Core Scientific shareholders vote to reject a $9B takeover bid by CoreWeave that proxy advisers said undervalued the data center company
Context & Ripple Effects
CoreWeave’s planned all-stock acquisition followed an earlier failed attempt to buy Core Scientific: the target had already rejected CoreWeave’s 2024 offer as too low. The companies nevertheless reached a roughly $9B agreement in July to add data-center capacity.
The deal then faced resistance from hedge-fund holders concerned about the stock consideration, and CoreWeave subsequently said it would not raise its offer. The shareholder vote turns that disagreement into a decisive constraint on the proposed combination.
First-order effects
- The acquisition cannot proceed on the agreed terms, leaving Core Scientific shareholders with continued exposure to the company rather than ownership of the combined business.
- CoreWeave loses its negotiated path to Core Scientific’s data-center footprint and must reassess how it secures capacity without this transaction.
Second-order effects
- Core Scientific’s board and investors gain leverage to assess standalone execution or alternative proposals, while any renewed CoreWeave approach would need to address the valuation objections that defeated the all-stock deal.
- Other owners of power-ready data-center assets may see stronger scrutiny of consideration, particularly where an acquirer’s share price materially shapes the value delivered to target shareholders.
Third-order effects
- If similar votes recur, AI-infrastructure consolidation may shift from stock-led acquisitions toward structures with clearer value protection for target investors, such as more cash certainty or revised exchange mechanics.
- The episode reinforces that scarce compute infrastructure is valuable but not automatically transferable through M&A: capital structure, shareholder approval, and asset valuation can constrain expansion as much as physical capacity.
The trend: AI-compute providers are pursuing vertical control of data-center capacity, but investor resistance is making the financing and valuation of those acquisitions a central competitive issue.